Preemptive oral treatment with sumatriptan during a cluster period

I. Monstad, A. Krabbe, G. Micieli, A. Prusinski, J. Cole, A. Pilgrim, P. Shevlin

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

This multinational, multicenter, randomized, double-blind, placebo- controlled study in 169 patients investigated the effect of a 7-day period of preemptive treatment with oral sumatriptan (100 mg tid) on the frequency and severity of cluster headache attacks occurring during an established cluster headache period. Safety and tolerability were also assessed. Cluster headache patients who were not taking prophylactic medication and had experienced seven or more attacks in the preceding observation week, treated a cluster headache attack at home with subcutaneous sumatriptan 6 mg using an autoinjector device. Patients were then randomized to take sumatriptan 100 mg or placebo at 8-hourly intervals for a 7-day period. Cluster headaches occurring during this period could be treated 5 minutes after onset with rescue medication (100% oxygen or simple analgesics). Diary cards were used to record details of the cluster headache pattern during the observation and study treatment weeks. Preemptive oral treatment with sumatriptan 100 mg tid for 7 days did not produce a significant reduction in the number or severity of cluster headache attacks occurring during an established cluster headache period. Oral treatment with sumatriptan 100 mg tid over a 7-day period was not associated with an increased or altered adverse event profile from that previously reported.

Original languageEnglish
Pages (from-to)607-613
Number of pages7
JournalHeadache
Volume35
Issue number10
DOIs
Publication statusPublished - 1995

Fingerprint

Sumatriptan
Cluster Headache
Therapeutics
Placebos
Observation
Analgesics
Oxygen
Safety
Equipment and Supplies

Keywords

  • cluster headache
  • efficacy
  • placebo- controlled
  • preemptive treatment
  • safety
  • sumatriptan

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Monstad, I., Krabbe, A., Micieli, G., Prusinski, A., Cole, J., Pilgrim, A., & Shevlin, P. (1995). Preemptive oral treatment with sumatriptan during a cluster period. Headache, 35(10), 607-613. https://doi.org/10.1111/j.1526-4610.1995.hed3510607.x

Preemptive oral treatment with sumatriptan during a cluster period. / Monstad, I.; Krabbe, A.; Micieli, G.; Prusinski, A.; Cole, J.; Pilgrim, A.; Shevlin, P.

In: Headache, Vol. 35, No. 10, 1995, p. 607-613.

Research output: Contribution to journalArticle

Monstad, I, Krabbe, A, Micieli, G, Prusinski, A, Cole, J, Pilgrim, A & Shevlin, P 1995, 'Preemptive oral treatment with sumatriptan during a cluster period', Headache, vol. 35, no. 10, pp. 607-613. https://doi.org/10.1111/j.1526-4610.1995.hed3510607.x
Monstad, I. ; Krabbe, A. ; Micieli, G. ; Prusinski, A. ; Cole, J. ; Pilgrim, A. ; Shevlin, P. / Preemptive oral treatment with sumatriptan during a cluster period. In: Headache. 1995 ; Vol. 35, No. 10. pp. 607-613.
@article{0ce715c2ec6047728076dcc0ac7d0a72,
title = "Preemptive oral treatment with sumatriptan during a cluster period",
abstract = "This multinational, multicenter, randomized, double-blind, placebo- controlled study in 169 patients investigated the effect of a 7-day period of preemptive treatment with oral sumatriptan (100 mg tid) on the frequency and severity of cluster headache attacks occurring during an established cluster headache period. Safety and tolerability were also assessed. Cluster headache patients who were not taking prophylactic medication and had experienced seven or more attacks in the preceding observation week, treated a cluster headache attack at home with subcutaneous sumatriptan 6 mg using an autoinjector device. Patients were then randomized to take sumatriptan 100 mg or placebo at 8-hourly intervals for a 7-day period. Cluster headaches occurring during this period could be treated 5 minutes after onset with rescue medication (100{\%} oxygen or simple analgesics). Diary cards were used to record details of the cluster headache pattern during the observation and study treatment weeks. Preemptive oral treatment with sumatriptan 100 mg tid for 7 days did not produce a significant reduction in the number or severity of cluster headache attacks occurring during an established cluster headache period. Oral treatment with sumatriptan 100 mg tid over a 7-day period was not associated with an increased or altered adverse event profile from that previously reported.",
keywords = "cluster headache, efficacy, placebo- controlled, preemptive treatment, safety, sumatriptan",
author = "I. Monstad and A. Krabbe and G. Micieli and A. Prusinski and J. Cole and A. Pilgrim and P. Shevlin",
year = "1995",
doi = "10.1111/j.1526-4610.1995.hed3510607.x",
language = "English",
volume = "35",
pages = "607--613",
journal = "Headache",
issn = "0017-8748",
publisher = "wiley",
number = "10",

}

TY - JOUR

T1 - Preemptive oral treatment with sumatriptan during a cluster period

AU - Monstad, I.

AU - Krabbe, A.

AU - Micieli, G.

AU - Prusinski, A.

AU - Cole, J.

AU - Pilgrim, A.

AU - Shevlin, P.

PY - 1995

Y1 - 1995

N2 - This multinational, multicenter, randomized, double-blind, placebo- controlled study in 169 patients investigated the effect of a 7-day period of preemptive treatment with oral sumatriptan (100 mg tid) on the frequency and severity of cluster headache attacks occurring during an established cluster headache period. Safety and tolerability were also assessed. Cluster headache patients who were not taking prophylactic medication and had experienced seven or more attacks in the preceding observation week, treated a cluster headache attack at home with subcutaneous sumatriptan 6 mg using an autoinjector device. Patients were then randomized to take sumatriptan 100 mg or placebo at 8-hourly intervals for a 7-day period. Cluster headaches occurring during this period could be treated 5 minutes after onset with rescue medication (100% oxygen or simple analgesics). Diary cards were used to record details of the cluster headache pattern during the observation and study treatment weeks. Preemptive oral treatment with sumatriptan 100 mg tid for 7 days did not produce a significant reduction in the number or severity of cluster headache attacks occurring during an established cluster headache period. Oral treatment with sumatriptan 100 mg tid over a 7-day period was not associated with an increased or altered adverse event profile from that previously reported.

AB - This multinational, multicenter, randomized, double-blind, placebo- controlled study in 169 patients investigated the effect of a 7-day period of preemptive treatment with oral sumatriptan (100 mg tid) on the frequency and severity of cluster headache attacks occurring during an established cluster headache period. Safety and tolerability were also assessed. Cluster headache patients who were not taking prophylactic medication and had experienced seven or more attacks in the preceding observation week, treated a cluster headache attack at home with subcutaneous sumatriptan 6 mg using an autoinjector device. Patients were then randomized to take sumatriptan 100 mg or placebo at 8-hourly intervals for a 7-day period. Cluster headaches occurring during this period could be treated 5 minutes after onset with rescue medication (100% oxygen or simple analgesics). Diary cards were used to record details of the cluster headache pattern during the observation and study treatment weeks. Preemptive oral treatment with sumatriptan 100 mg tid for 7 days did not produce a significant reduction in the number or severity of cluster headache attacks occurring during an established cluster headache period. Oral treatment with sumatriptan 100 mg tid over a 7-day period was not associated with an increased or altered adverse event profile from that previously reported.

KW - cluster headache

KW - efficacy

KW - placebo- controlled

KW - preemptive treatment

KW - safety

KW - sumatriptan

UR - http://www.scopus.com/inward/record.url?scp=0029587439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029587439&partnerID=8YFLogxK

U2 - 10.1111/j.1526-4610.1995.hed3510607.x

DO - 10.1111/j.1526-4610.1995.hed3510607.x

M3 - Article

VL - 35

SP - 607

EP - 613

JO - Headache

JF - Headache

SN - 0017-8748

IS - 10

ER -